The enzyme-activated irreversible inhibition of type-B monoamine oxidase by 3-{4- [(3-chlorophenyl) 
The activity of the mitochondrial enzyme monoamine oxidase [monoamine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.41 exists in two forms, one of which (the A-form) is sensitive to inhibition by low concentrations of the acetylenic inhibitor clorgyline whereas the other (the B-form) is sensitive to inhibition by deprenyl (Johnston, 1968; Knoll & Magyar, 1972) . These two forms also differ in their substrate specificities. Although such selectivity is not absolute (for discussion see Tipton et al., 1982) , at relatively low concentrations 5-hydroxytryptamine is a substrate essentially for the A-form alone whereas only the B-form has significant activity towards phenethylamine.
The compound 3-{4-[(3-chlorophenyl)methoxylphenyl } -5 -[(methylamino)methylI -2-oxazolidinone methanesulphonate (compound MD 780236) shown in Fig. 1 has been found to be a monoamine oxidase inhibitor with selectivity towards the B-form of the enzyme, but its behaviour in vivo has been found to differ from that in vitro (Strolin Benedetti et al., t Present address: Astra Lakemedel AB, S-15185 S6dertalje, Sweden. Vol. 209 1982). Inhibition by this compound in vitro was found to be irreversible, whereas the inhibition that resulted from administration of the compound in vivo was found mainly to be reversible. The present paper reports the results of studies designed to assess the mechanism of the inhibitory process in vitro with the aim of understanding the factors that might account for this behaviour.
Materials
The radioactive substrates 5-hydroxy[side-chain- Fowler & Tipton (1981) , with 5-hydroxytryptamine and phenethylamine as substrates for monoamine oxidase A-form and B-form respectively. The results were corrected for the efficiencies of extraction of the deaminated metabolites into the organic layer so that activities could be expressed as nmol/min per mg of protein . Activities were also determined fluorimetrically by following the production of H202 by coupling it to peroxidase-catalysed oxidation of homovanillic acid (Tipton, 1969) , a Perkin-Elmer MPF 44B fluorimeter connected to a Rikadenki chart recorder being used. All assays were performed at 370C in 100mM-potassium phosphate buffer, pH 7.2, and under free equilibrium with air. Protein, concentration was determined by the method of Markwell et al. (1978) , with bovine serum albumin as the protein standard.
Results and discussion
Initial experiments showed that preincubation of monoamine oxidase and compound MD 780236 was necessary in order to achieve full inhibition. The initial phase of inhibition of each of the two forms of monoamine oxidase was investigated by starting the reaction by the addition of enzyme to the substrate/inhibitor mixture. Short incubation times (2 min for phenethylamine and 5 min for 5-hydroxytryptamine) were used to ensure that no significant irreversible inhibition occurred during the assay period. Inhibition was found to be competitive with respect to both substrates (Fig. 2) , and K, values of 0.54,UM and 3.7,M towards phenethylamine and 5-hydroxytryptamine respectively were determined. As shown in Table 1 , similar K1 values were calculated from the IC50 values, determined in the absence of preincubation, by the method of Cheng & Prusoff (1973) .
Although the inhibition of the activity towards 5-hydroxytryptamine appeared to be strictly competitive at all inhibitor concentrations used, Fig to the B-form of the enzyme having significant activity towards high concentrations of 5-hydroxytryptamine (Tipton & Mantle, 1981; Fowler et al., 1982) . From this intercept effect the maximum velocity of monoamine oxidase B-form towards 5-hydroxytryptamine can be calculated to be about 18% of the total, in reasonable agreement with the value of 11% determined by a more direct approach . It can be seen from the values in Table 1 that in the reversible phase of the inhibition compound MD 780236 exhibits a relatively small degree of selectivity towards the B-form of the enzyme (K, for B-form/K1 for A-form ratio 1:6.9), whereas a much greater selectivity is evident after incubation of the enzyme and inhibitor for 90min (IC50 for Bform/IC50 for A-form ratio 1:80). These results suggest that, as has been observed for the inhibition of monoamine oxidase by (-)-deprenyl , the difference in affinities of the two forms for reversible interaction with the inhibitor must be further enhanced by large differences in the rates of reaction within the non-covalent complex to produce to irreversibly inhibited species. This suggests that compound MD 780236 acts as an enzyme-activated ('suicide' or kcat) irreversible inhibitor of monoamine oxidase, as has been shown to be the case for the propargylamine derivatives (see, e.g., Abeles & Maycock, 1976; Fowler et al., 1982) . The time-dependent inhibition of the monoamine oxidase activities by compound MD 780236 was studied by preincubating the enzyme for various times before assaying the activity towards 5-hydroxytryptamine or phenethylamine. As shown in Fig. 3(a) the inhibition of monoamine oxidase B-form activity showed a marked time-dependence, with inhibition reaching completion in less than 20min. After this time, dilution experiments showed the inhibition to be essentially irreversible ( Table 2 ).
The time-dependance of the inhibition of the A-form Of the enzyme was much less marked (Fig. 3b) Table 2 . Reversibility ofinhibition ofmonoamine oxidase A-form and B-form by compound MD 780236 Samples were preincubated with inhibitor for 30min at 370C and then either assayed directly for monoamine oxidase activity ('Before washing') or washed (by centrifugation of 1 ml of the mixture to sediment the mitochondria followed by resuspension in 1 ml of 100mM-potassium phosphate buffer, pH 7.2) three times before assay for enzyme activity ('After three washings'). Such a procedure gives an effective dilution of the inhibitor of more than 800 000: 1. The preincubation protein concentration was 0.31 mg/ml. Fig. 4 , is clearly non-linear. The possibility that the failure of excess inhibitor to cause complete inhibition of the B-form of the enzyme could be due to non-specific binding removing substantial proportions from the system was ruled out by the results of the experiments shown in Table 3 , where the inhibitor was preincubated with a sample of mitochondria that had been pretreated with a mixture of clorgyline plus deprenyl (0.3,UM of each) to inhibit all the monoamine oxidase activity (see Tipton et al., 1982) before the ability of this mixture to inhibit the activity of an equal amount of untreated mitochondria was determined. The results clearly show that there was no significant decrease in the inhibitory potency due to this preincubation, indicating that a non-specific binding of the inhibitor does not occur to any significant extent. The results Table 3 also indicate that destruction of the inhibitor by an enzyme other than monoamine oxidase does not occur to any significant extent under the conditions used here.
The failure of the inhibitor to cause complete inhibition is thus likely to be due to substantial metabolism of this compound by the action of monoamine oxidase itself. Two possible mechanisms whereby such degradation could occur have been considered in connection with the inhibition of other enzymes. A model in which the covalently bound enzyme-inhibitor complex is unstable and slowly decomposes to regenerate the free enzyme plus a modified form of the inhibitor according to the mechanism: E+1=EB 1 B-IE-B + P
( 1) where E -I and E-I represent the non-covalent and covalently bound enzyme-inhibitor complexes respectively, and P represents the modified form of the inhibitor, has, for example, been shown to describe the inhibition, of acetylcholinesterase by methylcarbamates (see, e.g., O'Brien, 1968) . In the present case, however, such a mechanism cannot account for the inhibition kinetics observed, since no significant recovery of the activity of the irreversibly inhibited B-form of the enzyme occurred during prolonged dialysis (Strolin or after repeated centrifugation and washing (Table 2 ).
Vol. 209 I I Table 3 . Effects of preincubation with clorgyline-plus-(-)-deprenyl-treated mitochondria on the inhibitory potency of compound MD 780236 towards monoamine oxidase B-form Samples of compound MD 780236 at the indicated concentrations were incubated in 100mM-phosphate buffer, pH 7.2, with either mitochondria (0.018 mg of protein) that had been treated with 0.34uM-clorgyline plus 0.3,UM-(-)-deprenyl to inhibit the monoamine oxidase activity (see Tipton et al., 1982) , or with an equal volume of the buffer, for 30min at 370C. Fresh untreated mitochondria were then added, and incubation was continued for another 30min before the activity was determined with phenethylamine as the substrate. Values are the means (± S.E.R.) of four separate determinations. showed that the rate of inhibition will be given by the equation:
where i represents the inhibitor concentration, k = (k+2k+4)/(k+2 + k+3+ k+4) and represents the catalytic constant for the overall flux, and K', which corresponds to the Michaelis constant of the system, is given by the relationship:
Such a mechanism predicts that compound MD 780236 should be a substrate for monoamine oxidase, and this was studied by determining the formation of H202, which is produced stoicheiometrically with amine oxidation (see, e.g., Tipton, 1969) , during reaction between the enzyme and inhibitor. Fig. 5 shows the time courses of the reaction when monoamine oxidase B-form was incubated with 500nM-compound MD 780236. The observation that product formation ceases rather than tends to a constant rate, long before the substrate has all been exhausted, is consistent with the mechanism represented by eqn. (2), rather than that of eqn. (1), being followed. Under conditions where the inhibitor is present in amounts that result in complete inhibition, the ratio of the amount of product formed to the enzyme concentration should be constant and correspond to the ratio k+3/k+4 (the partition ratio) (see Waley, 1980) . The results obtained at a number of different, saturating, inhibitor concentrations are shown in Table 4 , and correspond to a partition ratio of 530 + 16 (mean + S.E.M.). From the half-time of the inhibitory process determined at a series of different initial inhibitor concentrations values of k' and K' of 0.3 + 0.01 min-' and 0.36 + 0.03 4uM could be calculated according to the equation: 1 r-e 1-i Table 4 . Product formed at complete inhibition of monoamine oxidase B-form by compound MD 780236 The amount of H202 formed after complete inhibition were determined with three different mitochondrial preparations that had been pretreated for 1 h at 370C with 0.3,uM-clorgyline to inhibit the activity due to monoamine oxidase A-form (see Tipton et al., 1982) . The concentration of monoamine oxidase Bform in the preparations were determined by titrating the activity against the inhibitor compound J-508 as described by . By this technique a mean concentration of 20.5 pmol/mg of protein was found. The partition ratios were then calculated as (product formed)/(enzyme concentration) in the incubation medium (see Waley, 1980 where e and i are the initial enzyme and inhibitor concentrations respectively and r is the partition ratio k+3/k,4 (see Waley, 1980) . By using a mitochondrial preparation that had been incubated for lh at 370C with 0.3,UM-(-)-deprenyl to inhibit the B-form of the enzyme (see Tipton et al., 1982) , compound MD 780236 was found also to be a substrate for the A-form of monoamine oxidase. The progress curves of the reaction showed relatively little curvature, in agreement with the low efficiency of this compound as a time-dependent irreversible inhibitor of that form. The initial rate of the reaction was shown to be proportional to enzyme concentration, and Km and Vmax values of about 1. IpM and 4 nmol/min per mg of protein were calculated from half-reciprocal (Hanes) plots of the dependence of rates on substrate concentration (Fig. 6 ). This Km value is quite similar to the K1 value of 3.7, M determined for compound MD 780236 as a reversible inhibitor of 5-hydroxytryptamine oxidation.
In systems containing only the B-form of monoamine oxidase, the extent of irreversible inhibition obtained will be governed by its concentration and the ratio of the rate constants for breakdown and irreversible inhibition (the partition ratio, k+3/k+4).
The behaviour of systems containing both forms of the enzyme will be further complicated by the activity of the A-form towards this compound.
The nature of the product formed by the action of monoamine oxidase is not revealed by the present studies. However, both the acidic and alcoholic metabolites of compound MD 780236 have been Vol. 209 shown to be formed in rat after the administration of the inhibitor in vivo (Strolin Benedetti & Dow, 1982 
